Recently, epidemiological and clinical data have revealed important changes with regard to clinical adenovirus infection, including alterations in antigenic presentation, geographical distribution, and virulence of the virus.
mately 50% of infections were asymptomatic, and symptomatic infections were typically mild and resolved without sequelae. In contrast, military populations experienced severe epidemics of acute respiratory disease, including pneumonia and encephalitis, especially involving adenovirus types 4, 7, and 21. For example, in 1958, adenoviral infection was reported to have caused hospitalization of an estimated 10% of military recruits [6] and to be the etiology of most respiratory disease during winter months. Subsequently, vaccines for adenovirus types 4 and 7 were developed and effectively used among US military trainees from the 1970s until the late 1990s [7, 8] . Thus, until recently, adenovirus infection was considered to have little consequence, except for causing morbidity among military trainees.
However, much has changed since these early epidemiological studies were conducted. In contrast to the modest number of adenovirus types recognized 35 years ago, 51 unique serotypes are now recognized. Different serotypes have been found to have different tissue tropisms that correlate with different clinical manifestations of infection. Limited epidemiological investigations have revealed that, among some specific serotypes, multiple genetic variants exist that often have quite different geographical distributions and associated virulence [9] [10] [11] . In addition, largely because of molecular diagnostics, adenovirus infection has been associated with a number of acute and chronic diseases, including chronic airway obstruction [12] and pulmonary dysplasia [13] , myocarditis and dilated cardiomyopathy [14] , mononucleosis-like syndromes [15] , intussusception [16] , sudden infant perinatal death [17] , and obesity [18, 19] . Among some population groups, adenoviral infection is common and, often, severe. For example, the incidence of adenoviral disease among bone marrow transplant recipients varies from 3% to 20% [20] , and mortality can exceed 50% [21] . Similarly, multiple recent outbreaks of adenoviral infection in the United States have frequently occurred among institutionalized children and in medical settings, resulting in significant morbidity and mortality among patients and medical staff [22] . In vitro studies suggest that specific adenovirus types are more likely to respond to certain antiviral therapies [23] . Finally, since the military lost its manufacturer of adenovirus types 4 and 7 vaccines in the late 1990s, numerous outbreaks of adenovirus infection have occurred among military trainees, resulting in great morbidity [24, 25] . Subsequently, the US Department of Defense identified a new vaccine manufacturer, and restoration of adenovirus types 4 and 7 vaccines is projected for 2008 [25] . It seems prudent to investigate whether previously very effective and safe vaccines may also benefit some nonmilitary populations. Therefore, an updated look at the epidemiology of human adenovirus infection is warranted. In this report, we present 25 months of viral and patient epidemiological data on clinical adenovirus infection detected through a nationwide network of 22 US military and civilian medical facilities. We used a recently described molecular adenovirus typing technique to characterize the strains of adenovirus [26] .
MATERIALS AND METHODS

Population. From July 2004 through September 2006
, specimens that were positive for adenovirus by rapid diagnostic test, PCR, or culture were collected from 22 US medical facilities. Of these facilities, 8 were military sites located in California, Georgia, Illinois, Missouri, New Jersey, South Carolina (2 sites), and Texas, and 14 were civilian laboratories located in Arizona, Colorado, Connecticut, Indiana, Florida, North Carolina, New York (2 sites), Missouri (2 sites), Tennessee, Texas, Washington, and Wisconsin. Samples were collected as part of routine testing, labeled with unique study identifiers, and sent to the University of Iowa Center for Emerging Infectious Diseases (Iowa City) for genetic typing. This study was approved by the multiple institutional review boards representing the participating laboratories.
As part of routine viral respiratory pathogen surveillance [25] , the military laboratories first submitted specimens to the Navy Respiratory Disease Laboratory in San Diego, California. Each month, after viral identification work, the Navy laboratory shared a sample set of ∼30 specimens with the Center for Emerging Infectious Diseases. This sample set represented specimens that were positive for adenovirus from each of the 8 sites, distributed over time. For adenovirus-positive specimens, the Navy laboratory provided the specimen collection date and the age, sex, and training site of the patient from whom the specimen was obtained.
Civilian laboratories were asked to submit all adenoviruspositive specimens. Limited demographic and clinical data were obtained from each civilian specimen, including the laboratory collection site (city and state), collection date, specimen source (e.g., nasal, pharyngeal or blood), and specimen type (e.g., culture, direct fluorescent antibody, or PCR), as well as patient birth date and sex, whether the patient was hospitalized when the specimen was collected, and whether the patient had undergone transplantation during the 6 months prior to specimen collection. Because of their risk for severe disease, additional information (race and ethnicity, clinical presentation, hospitalization care, disposition, cancer status, and chronic disease status) was obtained from patients with adenovirus infection who were aged !7 years or who had undergone transplantation within 6 months before the positive adenovirus result. The cutoff value of !7 years of age was based on a recent investigation of an outbreak of adenovirus type 7d2 infection (among 93 patients, with a 33% attack rate and 8 deaths), in which children aged !7 years were found to be at increased risk for illness [22] .
DNA extraction, PCR, and sequencing. After an initial study, we found that most adenovirus-positive specimens yielded PCR amplification products without requiring additional culture enrichment. Viral DNA was extracted from 200 mL of the original adenovirus-positive specimen in a final elution volume of ∼200 mL using the QIAamp DNA Blood Mini Kit (Qiagen). An initial volume of 5 mL of eluted sample was amplified using a PCR procedure that targeted hypervariable regions 1-6 of the hexon gene [26] . M13 universal priming tails (forward, 5 -TGT AAA ACG ACG GCC AGT-3 ; and reverse, 5 -CAG GAA ACA GCT ATG ACC-3 ) were added to the previously described primers to facilitate sequencing. Expected amplicons from this reaction ranged from 764 to 896 bp in length. These amplicons were then sequenced on a 3730 xl DNA Analyser (Applied BioSystems). The forward and reverse sequences were combined using BioEdit (Ibis Therapeutics) and were compared with the similar sequences of 51 wellcharacterized prototype viruses and other well-characterized genotypes from our collections and from GenBank. Specimens that yielded identity scores у90%, compared with both our internal sequence database and that of GenBank, were considered to be good genotype matches.
Culture. When PCR amplification failed, the original specimen was inoculated into A549 cells (ATCC) and incubated at 37ЊC for 4-7 days or until a cytopathic effect was observed. If, after 7 days, no cytopathic effect was detected, cells were cultured again. After cytopathic effect was confirmed, the positive cell culture specimen was characterized by PCR and sequencing.
Validation. A systematic sample of 101 adenovirus-positive specimens containing numerous genotypes was shared with the Viral and Rickettsial Disease Laboratory of the California Department of Health Services (Richmond) for blinded validation using classic serotyping techniques. This laboratory shared 3 of these specimens with the Navy Respiratory Disease Laboratory for further study using a PCR adenovirus typing algorithm [27] .
Statistical analyses. Questionnaire and laboratory data were linked by the unique specimen number. In instances in which several adenovirus-positive specimens were obtained from the same patient and clinical event, the linkage of these specimens was indicated by the civilian laboratories using study forms. During studies of clinical outcomes, only the first adenovirus-positive specimen was considered in studies of clinical events. The x 2 test and Fisher's exact test were used to examine potential risk factor associations. The exact Cochran-Armitage test for trend was used to examine adenovirus genotype prevalence across years. Logistic regression modeling was used to examine potential risk factors for outcomes, such as pneumonia. The proportional odds model was used to examine risk factors for severe adenovirus infection, considering the outcomes of hospitalization, intensive care unit stay, and death in a mutually exclusive, ordinal severity scale based on data on the first adenovirus-positive specimen for the clinical event.
These 3 final multivariable models were derived using a saturated model and manual backwards elimination. Analyses were performed using SAS, version 9.1 (SAS Institute).
RESULTS
Validation.
In the blinded validation study, 98 (97%) of the 101 adenovirus-positive specimens were typeable using typespecific neutralization. Serotyping agreed with genotyping for all 98 specimens. The remaining 3 specimens of unknown types were studied using a novel and quite different PCR typing algorithm [27] , and the blinded results of this algorithm were in agreement with University of Iowa genotyping methods.
Genotyping by PCR and sequencing. During the study period, 2237 adenovirus-positive specimens were received (1653 specimens from civilians and 584 from military trainees). All of the specimens from military trainees resulted from culture. Specimen type information was available for 1170 specimens from civilians; 84.9% of specimens were isolated by culture, 7.9% by direct fluorescent antibody, and 7.2% by PCR assays. Ninety-eight percent of the 2237 adenovirus-positive specimens were successfully typed by PCR and sequencing. Of the 47 initially nontypeable specimens, 27 (57.4%) were eventually typed after statistical analysis had been concluded, 4 (8.5%) were not confirmed to be positive for adenovirus by PCR, and 16 (34.0%) were confirmed to be positive for adenovirus by PCR, but the sequence data were inconclusive. The samples that were not confirmed to be positive for adenovirus by PCR may represent false-positive specimens or specimens with low viral titer that did not yield adenovirus by culture. The samples confirmed to be positive for adenovirus by PCR that had inconclusive sequence data may represent dual adenovirus infections or infection with novel viruses. We are further analyzing these specimens.
The 582 successfully typed specimens from military trainees were comprised primarily of adenovirus hexon sequence genotypes (HSgenotypes) 4 (92.8% of specimens), 3 (2.6%), and 21 (2.4%) (table 1). The age and sex distribution of patients with adenovirus infection were consistent with the demographic characteristics of military training populations. During the study period, there was a statistically significant increasing trend in the prevalence of adenovirus type 21 isolates and a decreasing trend in the prevalence of type 4 isolates. These data represent only a small subset and limited time distribution of adenovirus isolates found in specimens from military trainees. Detailed analyses of a more comprehensive sample set are the subject of a separate report (K.L.R., unpublished data).
Specimens from civilians yielded a more diverse distribution of adenovirus HSgenotypes, with 23 different types detected (table 2) . Among the 1608 adenovirus-positive specimens successfully typed, 76.8% were from children aged !7 years, 59% were from male patients, 71.0% were from upper respiratory tract sites, and 49.6% were associated with hospitalization. The most prevalent adenovirus HSgenotypes were types 3 (34.6% of specimens), 2 (24.3%), 1 (17.7%), and 5 (5.3%). The distribution of HSgenotypes differed by age group (with types 1 and 2 being more prevalent among patients aged !7 years) and by specimen source (with types 1, 3, and 2 being most prevalent among blood, upper respiratory tract, and gastrointestinal tract specimens, respectively). For the 1059 unique clinical events experienced by patients with adenovirus infection who were aged !7 years or who had undergone transplantation within 6 months prior to specimen collection, more clinical information was obtained. Of these patients, 95.3% were aged !7 years, 58.9% were male, 11.0% reported to have recently received a transplant, and 4.2% had received a diagnosis of cancer (table 3) . Sixty-seven (57.8%) of the 116 transplant recipients had received a bone marrow transplant (data not shown). Thirty-four (58.8%) of the 45 patients with cancer had cancer of lymphatic and hematopoietic origin (data not shown). Four hundred fifty (42.5%) of the 1059 patients with adenovirus infection presented with upper respiratory tract infection. Two hundred fifty-five patients (24.1%) were hospitalized for у4 days (median duration of hospitalization, 3 days). Two hundred eight patients (19.6%) had a chronic disease, and 78 (7.4%) had stayed in an intensive care unit. Because certain populations were thought to be at risk of severe adenovirus infection, the characteristics of patients aged !7 years were stratified by immune status and compared with the characteristics of immunocompromised patients aged у7 years (table 4) . In general, nonimmunocompromised children aged !7 years experienced more adenovirus type 3 infections and more upper respiratory tract infections than did immunocompromised children aged !7 years; however, the nonimmunocompromised children had less severe disease and were less likely to have numerous adenovirus isolates per clinical event.
A number of laboratories submitted multiple adenoviruspositive specimens for a single clinical event. Most of these specimens were of the same genotype; however, 20 unique clinical events were found to be associated with laboratory evidence of infection with у2 adenovirus HSgenotypes (table 5). Most of these infections involving multiple adenovirus HSgenotypes occurred in immunocompromised patients who were aged !7 years.
The multivariable risk factor modeling (table 6) for adenovirus disease severity (death or intensive care unit stay vs. hospitalization vs. other disease) revealed some interesting findings. As expected, patients aged !7 years (OR, 3.2; 95% CI, 1.4-7.4), patients with chronic disease (OR, 3.6; 95% CI, 2.6-5.1), and patients who had recently undergone transplantation (OR, 2.7; 95% CI, 1.3-5.2) had an increased risk of severe disease. However, unexpectedly, patients infected with adenovirus type 5 (OR, 2.7; 95% CI, 1.5-4.7) or 21 (OR, 7.6; 95% CI, 2.6-22.3) also had a higher risk of developing severe adenovirus disease. Similar multivariable modeling was performed (22) 7 (14) 5 (10) 2 (4) 6 (12) 1 (2) 2 (4) 1 (2) for the outcome of pneumonia, but no specific adenovirus types were associated with this condition (data not shown).
DISCUSSION
Sequencing of hypervariable regions 1-6 of the adenovirus hexon gene [26] appears to correlate well with serological and other molecular methods for typing human adenovirus and, unlike serological methods that can take weeks to perform, can generally be completed within 2 days. It is likely that PCR and sequencing will replace older, classic adenovirus serotyping methods, because PCR and sequencing have the potential to provide rapid results to clinicians and public health officials evaluating and treating specific patients and responding to outbreaks of adenovirus infection. Conversion from classic serotyping to genotyping of adenovirus is not unlike similar recent shifts for the study of group A streptococci [28] and enterovirus [29] . Typing results yielded some interesting observations. The high prevalence of infection with adenovirus type 4 HSgenotypes among patients in the military is consistent with a recent report [25] . However, the increased prevalence of adenovirus type 21 infection among both military and civilian patients was unexpected (tables 1 and 2). Because prevalence figures for adenovirus infection have been known to fluctuate over time, these changes were not significantly alarming. However, adenovirus type 21 infection has caused sporadic outbreaks among military [30] [31] [32] and civilian populations [33, 34] , and changes in prevalence must be evaluated as possible indicators of the emergence of a novel strain. Because of such outbreaks, adenovirus type 21 vaccine development efforts were attempted [30, 35, 36] but never finalized, because morbidity associated with adenovirus 21 infection has remained low [7] . The high prevalence of hospitalization among the patients with adenovirus infection (table 2) was surprising. This may reflect the desire of clinicians to more frequently determine the etiology of an infection in patients sick enough to merit hospitalization. However, this high prevalence of hospitalization, the significant number of patients with adenovirus infection who require hospitalization in an intensive care unit, and the relatively long duration of hospitalization that is experienced for patients with adenovirus infection reflect the impact on morbidity that adenovirus infection has in US medical care facilities today.
Before this surveillance effort was initiated, adenovirus type 7 infection was predicted to have a strong association with severe morbidity. Worldwide, various adenovirus type 7 genotypes have emerged to cause epidemics and severe disease [9, [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] . However, thus far in this surveillance, adenovirus type 7 infection has not been implicated to have a strong association with severe morbidity. This could be because of a stabilization of circulating adenovirus type 7 genotypes in the United States-as was recently apparent in Iowa for the strain adenovirus type 7d2 [10] -with subsequent increases in herd immunity and reductions in adenovirus type 7 infections. Previous reports have noted that outbreaks of adenovirus type 7 infection seem to be sporadic [40, 48] and may be the result of the emergence of new type 7 subtypes [9, 40, 48] .
The association of adenovirus types 5 and 21 with severe disease (table 6) was unexpected. Although adenovirus types 5 and 21 are associated with novel strains [49] , epidemics [33, 34, 50, 51] , severe disease [52] , and death [53] , these observations have been relatively rare. Our data revealed that, of the 13 patients with adenovirus infection who died, 1 had been be associated with more frequent or more severe disease, as well as the unexpected lack of such associations with adenovirus type 7, merit further molecular investigation to determine whether there are viral predictors of disease severity. Finally, our findings that clinical adenovirus infection was often associated with hospitalization and that, more often than expected, multiple adenovirus types could be detected add to our new appreciation of the morbidity associated with adenovirus infection.
